<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined the efficacy of thalidomide in 34 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>): five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>, four <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, six <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, and 16 RA </plain></SENT>
<SENT sid="1" pm="."><plain>Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 <z:mpath ids='MPATH_458'>normal</z:mpath> karyotypes, four cases with 5q- as sole anomaly and three single aberrations </plain></SENT>
<SENT sid="2" pm="."><plain>The median thalidomide dose was 400 mg/day (25/34 patients) </plain></SENT>
<SENT sid="3" pm="."><plain>Four patients discontinued the study after less than 5 weeks, because of <z:mp ids='MP_0002899'>fatigue</z:mp> (three) or <z:hpo ids='HP_0000988'>skin rash</z:hpo> (one) </plain></SENT>
<SENT sid="4" pm="."><plain>One patient died of <z:hpo ids='HP_0001635'>heart failure</z:hpo> after 4 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>In the remaining 29 patients (median follow-up: 13 months), treatment responses were classified according to the IWG criteria </plain></SENT>
<SENT sid="6" pm="."><plain>Six patients (four RA, two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) showed progressive disease (five with transformation into <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and four patients showed stable disease </plain></SENT>
<SENT sid="7" pm="."><plain>Hematological improvement (HI) was observed in 19 patients </plain></SENT>
<SENT sid="8" pm="."><plain>Nine of the responders (three RA, one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) achieved partial remission with granulocytes &gt; or = 1500/microl, Hb &gt; 11 g/dl and platelets &gt; or =100,000/microl </plain></SENT>
<SENT sid="9" pm="."><plain>Four patients (one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) had a major response, with platelet and RBC transfusion independence </plain></SENT>
<SENT sid="10" pm="."><plain>Six patients (five RA, one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) showed minor responses (three HI-E, two HI-E+HI-P, one HI-E+HI-N) </plain></SENT>
<SENT sid="11" pm="."><plain>Hematological improvement occurred after a median of 2 months of thalidomide treatment </plain></SENT>
<SENT sid="12" pm="."><plain>Two patients (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) relapsed after a partial remission lasting 8 and 16 months, respectively </plain></SENT>
<SENT sid="13" pm="."><plain>In summary, a therapeutic benefit was achieved in 19 of 34 study patients (56%) </plain></SENT>
</text></document>